Shire Ups Mass. Expansion Plans

Xconomy Boston — 

Shire, the Irish drug company that keeps the headquarters of its Human Genetic Therapies unit in Massachusetts, told the Boston Globe yesterday that the firm plans to invest $460 million in its new campus in Lexington, MA, and hire 750 new workers in the Bay State over an eight-year period—increasing the scope of its plans announced last year to invest $394 million and add 680 employees in the state during that span of time. Sylvie Gregoire, president of Shire’s HGT business, talked to Xconomy late last year about the reasons for the expansion.